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Abstract
Background: Despite its effectiveness in the treatment of various cancers, the use of doxorubicin is limited by a potentially
fatal cardiomyopathy. Prevention of this cardiotoxicity remains a critical issue in clinical oncology. We hypothesized that
flavaglines, a family of natural compounds that display potent neuroprotective effects, may also alleviate doxorubicin-
induced cardiotoxicity.
Methodology/Principal Findings: Our in vitro data established that a pretreatment with flavaglines significantly increased
viability of doxorubicin-injured H9c2 cardiomyocytes as demonstrated by annexin V, TUNEL and active caspase-3 assays. We
demonstrated also that phosphorylation of the small heat shock protein Hsp27 is involved in the mechanism by which
flavaglines display their cardioprotective effect. Furthermore, knocking-down Hsp27 in H9c2 cardiomyocytes completely
reversed this cardioprotection. Administration of our lead compound (FL3) to mice attenuated cardiomyocyte apoptosis
and cardiac fibrosis, as reflected by a 50% decrease of mortality.
Conclusions/Significance: These results suggest a prophylactic potential of flavaglines to prevent doxorubicin-induced
cardiac toxicity.
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Introduction
Anthracyclines are among the most effective anticancer drugs
available with antitumor activity against both hematopoietic and
solid tumors [1,2]. However, their clinical utility is markedly
hampered by a major risk of cardiotoxicity that may lead to dilated
cardiomyopathy and congestive heart failure [3–6]. For example,
36% of adults treated with anthracyclines display cardiac
dysfunction and the risk of developing a congestive heart failure
reaches 48% for a cumulated dose of 700 mg/m
2. This
cardiotoxicity is even more exacerbated in pediatric and elderly
population. In a study on childhood leukemia, 57% of the 115
survivors had echocardiographic abnormalities in heart function
[5]. Considering that more than 50% of long-term survivors of
childhood cancer were treated with an anthracycline, cardiotox-
icity of this class of medicine is a widely prevalent problem that
cannot be ignored [6].
While the anticancer properties of anthracyclines is due to the
inhibition of topoisomerase II, their cardiotoxicity is caused by
other mechanisms that involve apoptosis mediated by calcium
overload and iron-catalyzed formation of free radicals.
Flavaglines constitute a family of compounds isolated from
medicinal plants of Southeast Asia that display a unique array of
pharmacological effects [7,8]. Recently, these compounds have
been reported to reduce MPP-induced mesencephalic cell toxicity
in a model of dopaminergic neuronal cell damage [9]. A similar
effect was observed in vivo, when mice were challenged with the
neurotoxin MPTP, as a model of Parkinson’s disease [9]. This first
report of the cytoprotective potential of flavaglines prompted us to
examine whether these compounds could have also cardioprotec-
tive properties. Indeed, cardiomyocytes and neurons have been
shown to share similar mitochondrial-dependent and -independent
mechanisms for death and survival [10–13].
In this study, we investigated the cardioprotective potential of
synthetic flavagline analogs FL1–4 in cellular and animal models
of doxorubicin-induced cardiotoxicity. The mechanism by which
FL3 leads to cardioprotection was also examined.
Materials and Methods
Materials
Flavaglines FL1–4 were synthesized in our laboratory [14].
KRIBB3 and doxorubicin were purchased from Sigma-Aldrich
(Saint-Quentin Fallavier, France). Rabbit polyclonal anti-phos-
pho-Hsp27 (Ser 15) antibody, rabbit polyclonal anti-Hsp27
antibody and horseradish peroxidase–conjugated secondary goat
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Biotechnology, Santa Cruz, CA, USA). Enzyme-linked chemilu-
minescence for Western blot analyses was purchased from
Amersham (Amersham Biosciences, Indianapolis, IN, USA).
Hsp27 siRNA antisense and control siRNA, a siRNA sequence
not homologous to any known gene, were chemically synthesized
by Ambion (Austin, TX, USA). Lipofectamine 2000 was the
transfection agent used and was purchased from Invitrogen
(Invitrogen, Cergy-Pontoise, France).TdT-mediated dUTP nick
end-labeling (TUNEL) assay was purchased from Millipore
(Billerica, MA, USA). Male BALB/cByJ mice were purchased
from Charles River (Charles River, l’Arbresle, France).
Cell culture
The H9c2 cardioblast cell line derived from embryonic rat heart
was obtained from American Type Culture Collection (Manassas,
VA, USA). Cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum at
37uCi n5 %C O 2. The medium was changed every 2–3 days.
Cell culture and experimental design of in vitro
cardiotoxicity assay
H9c2 cells were plated for 24 h in 100 mm Petri dishes at
7610
3 cells/cm
2. Next, the cells were washed and cultured for
12 h in glucose-free medium (Gibco, DMEM w- L-glutamine, w/o
D-glucose, sodium pyruvate) supplemented with only 1% fetal calf
serum. Cells were then treated with flavaglines FL1–4 or their
vehicle for 10 h and then were treated with doxorubicin for an
additional 14 h. The doxorubicin concentration and incubation
time were chosen as an acute model of cardiotoxicity [15].
KRIBB3 (1 uM) was preincubated for 1 h before flavaglines and
treatment in cardiomyocytes. Cells were washed, and subsequently
FACS analyses were performed. Unless it is indicated as a chronic
model, acute model of doxorubicin-induced cardiotoxicity was
used.
Serum withdrawal-induced cardiotoxicity
H9c2 cells were plated for 24 h in 100 mm Petri dishes at
7610
3 cells/cm
2. Next, the cells were washed and cultured for
12 h in glucose-free medium (Gibco, DMEM w- L-glutamine, w/o
D-glucose, sodium pyruvate) supplemented with only 1% fetal calf
serum. Cells were then treated with flavagline FL3 (20 nM) or
their vehicle for 24, 48 and 72 h. Cells were washed, and
subsequently FACS analyses were performed [16].
FACS analysis
Apoptosis was analyzed by fluorescence-activated cell sorting
analysis (FACS-Calibur, Becton-Dickinson Biosciences) [16].
7610
3 Cells were harvested and washed with Annexin Binding
Buffer (0.01 M HEPES, 0.14 M NaCl, 2.5 mM CaCl2) and
labeled with annexin V (dilution 1:50) and propidium iodide
(6.7 mg/ml). All assays were performed at least in triplicate, and
the results were analyzed by BD Cell Quest Pro software (Becton-
Dickinson Biosciences, Le Pont De Claix, France).
Western Blotting
H9c2 cells were plated for 24 h on 60 mm Petri dishes at
1.5610
4 cells/cm
2. Next, cells were washed and cultured for 12 h
in glucose-free medium (Gibco, DMEM w- L-glutamine, w/o D-
glucose, sodium pyruvate) supplemented with only 1% fetal calf
serum. Cells were then incubated with FL3 or vehicle for 1 h or
4 h and, after appropriate treatment, washed twice with
Phosphate-Buffered Saline (PBS). Cells were harvested with lysis
buffer (50 mM Tris-Hcl, 1 mM EDTA, 100 mM NaCl. 0.1%
SDS, 1% NP-40, 1 mM Na3VO4, 1 ug/mL aprotinin, 1 ug/mL
pepstatin, 1 ug/mL leupeptin, pH=7). Whole cell lysates were
centrifugated at 12000 g for 15 min at 4uC.The debris were
eliminated and 20 mg of protein were separated under denaturing
conditions using 12% SDS-PAGE and transferred to a poly-
vinylidene difluoride membrane. Blots were then incubated with a
blocking solution containing 5% fat-free milk powder in PBS plus
Tween (0.5% Tween 20) (PBS-T) at room temperature for 1 h.
After three washes with PBS-T for 10-min intervals, blots were
incubated overnight at 4uC under gentle shacking with respective
primary antibody (rabbit polyclonal anti-phospho-Hsp27 (1:500);
rabbit polyclonal anti–Hsp27 (1:500)) diluted in PBS-T containing
0.5% fat-free milk powder. After three washes with PBS-T,
membrane was incubated for 1 h at room temperature under
gentle shacking with a horseradish peroxidase–conjugated second-
ary goat anti-rabbit IgG (1:1000 dilution) in PBS-T containing
0.5% fat-free milk powder. The expected bands were visualized
after incubation by enzyme-linked chemiluminescence for 5 min
and quantified by scanning laser densitometry, normalizing to
total amounts of the corresponding proteins.
siRNA transfection
H9c2 cells at 3.5610
3 cells/cm
2 were plated on 100 mm Petri
dishes in media without antibiotics overnight before siRNA
administration. Transfection of siRNA was completed following
the protocol of the Lipofectamine 2000 manufacturer. The cells
were placed in a 5% CO2 incubator at 37uC and 8 hrs after
siRNA administration the media was replaced with fresh media
without antibiotics. After 48 hrs total elapsed time, the cells were
treated with FL3 (100 nM) for 10 h and then were treated with
doxorubicin for an additional 14 h. Hsp27 siRNA (Cat #54502)
and a negative control siRNA (Cat #4611) were purchased from
Ambion [17]. The working concentration of siRNA in cell
experiments was 30 nM. Data not shown: expression of Hsp27
in H9c2 cells transfected with siRNA for Hsp27 was reduced by
73%. Note that the expression of Hsp27 was not altered in H9c2
cells transfected with scrambling control siRNA.
Animals
Male BALB/cByJ mice at 10 weeks (25–30 g) were divided into
5 groups. At day 0, doxorubicin or FL3+doxorubicin group
received intraperitoneally (i.p.) a single dose of doxorubicin
(Sigma) dissolved in 0.9% NaCl at 15 mg/kg [18]. At day 23,
22, 21, 0 and +3, FL3+doxorubicin, or FL3 group received (i.p.)
a single dose of FL3 (0.1 mg/kg diluted in 20% of PEG 400). The
vehicle groups received (i.p.) 20% PEG 400 diluted in water for the
indicated date similar to FL3 group. Animal viability and body
weight was recorded daily for 10 days.
Histopathology and fibrosis
On day 10, after measurement of body weight, mice were killed.
The heart tissue was fixed and 5 mm-thick paraffin sections were
stained with Mallory tetrachrome staining for histological analysis
[19]. Quantification of the fibrosis (blue staining) was performed as
total pixel density of 20 individual, randomly selected fields from
10 different heart sections (n=2 for each group), using NIH
ImageJ.
Detection of apoptosis
TUNEL analysis of fragmented DNA was performed according
to the protocol of the manufacturer (Chemicon) as previously
described [20]. Cells were pretreated with different concentrations
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its vehicle were added to the medium. A maximum and stable
number of apoptotic cells were obtained within 24 h as a chronic
model of cardiotoxicity. Cells were then fixed in 4% formaldehyde
and permeabilized. After being washed, slides were incubated with
TdT terminal transferase and fluorescein-dUTP. Slides were
counterstained with DAPI. Cells were scored for TUNEL-positive
nuclei corresponding to condensed DAPI stained nucleus. The
percentage of TUNEL-positive cells was evaluated by viewing
each field at 640 magnification. Generally, 10 different micro-
scopic fields containing 10–15 cells each were recorded for each
sample. Each experiment was repeated at least three times.
Cryosectioned mice heart samples were obtained 10 days after the
treatments and then TUNEL assay was performed following the
manufacturer’s protocol. Slides were counterstained with DAPI
and then were analyzed by fluorescence microscopy followed by
quantification of the FITC total pixel density of 20 individual
randomly selected fields from 10 different heart sections (n=2 for
each group), using NIH ImageJ.
Analysis of Gene expression by RT-PCR
Total RNA from adult mice hearts was isolated using
TRIHReagent (Molecular research Center) and treated with
DNase using the RNase-Free DNase Set. Semi-quantitative RT-
PCR was performed on 0.5–5 mg of total RNA extracted from all
hearts, using GAPDH as an internal control. The primers are
shown in Supplementary Table S1.
Statistic analysis
Data are expressed as mean 6 SEM. Multigroup comparisons
were performed using one-way ANOVA with post hoc correction.
Comparisons between two groups were made using unpaired
Student’s t test. For all analyses, P,0.05 was considered significant
utilizing Prism.
Results
Flavaglines protect cardiomyocytes against doxorubicin
toxicity
The cellular activity of flavaglines was assessed using rat H9c2
cardiomyoblast cell lines that represent an established model to
study doxorubicin-induced cardiotoxicity in vitro [21]. Excitingly,
preincubation of H9c2 cells for 10 h with different concentrations
of flavaglines significantly promoted cardioprotection against acute
doxorubicin-induced apoptosis (Fig. 1, *P,0.01). None of these
compounds alone had any perceptible proapoptotic effects (data
not shown). The rank of cardioprotection by flavaglines in H9c2
cardiomyocytes was: FL2<FL4%FL1,FL3 (Figure 1). The most
active compound, FL3, displayed maximum cardiomyocyte
protection against doxorubicin-induced apoptosis by 6163 and
6763% at 50 and 100 nM concentrations respectively. Thus we
concentrated on FL3 for the rest of our study.
Next, we examined whether FL3 protects cardiomyocytes
against an acute as well as a chronic treatment of doxorubicin.
Figure 2A shows that incubation of the cells with 1 mM
doxorubicin for 14 h (acute model) induced 22.760.8% apoptosis
detected by FACS analysis utilizing Annexin V and PI.
Pretreatment of the H9c2 cells with FL3 at 100 nM drastically
reduced the proportion of apoptotic cell populations (Figure 2A,
n=4, *P,0.01). Figure 2B shows an original illustration of total
apoptotic cell populations detected by FACS analyses. FL3
significantly reduced total apoptotic cell numbers induced by
doxorubicin, in a dose dependent manner. The effect of FL3 was
also examined in a chronic model of doxorubicin-mediated
apoptosis by TUNEL staining. Indeed, FL3 significantly reduced
apoptosis induced by a 24 h treatment of H9c2 cells with
doxorubicin (1 mM), in a dose dependent manner (Figure 2C
and 2D, n=3, *P,0.001). The same results was observed when
H9c2 cardiomyocytes where grown in a complete medium (Figure
S1). Next, we investigated the effect of FL3 on activity of caspase-
3, a downstream effector of apoptosis, using Western blot analysis
with an antibody specific for the active (cleaved) form of caspase-3.
Pretreatment by FL3 (100 nM) induced a 63% reduction in
caspase-3 activity as compared to doxorubicin treatment alone,
clearly confirming a cardioprotective effect of FL3 in H9c2 cells
(Fig. 2E, n=3, *P,0.01).
FL3 protects cardiomyocytes against serum starvation
To further explore the scope of flavagline cardioprotection, we
examined whether FL3 could also protect H9c2 cardiomyocytes
against serum starvation-mediated apoptosis. H9c2 cells were
incubated with or without FL3 (20 nM) in the presence of 1%
serum for 24 h, 48 h and 72 h and apoptosis was detected by
FACS analyses. Maximum apoptosis was detected 72 h after
serum withdrawal. Remarkably, in accordance with its protective
efficacy against doxorubicin-induced apoptosis, FL3 diminished
apoptosis by 50%, 72 h after serum starvation (Figure 3, n=3,
*P,0.01).
FL3 cardioprotection is mediated through HSP27
phosphorylation
To examine the signaling mechanism involved in FL3-mediated
cardioprotection, pharmacological inhibitors of pro-survival ki-
nases such as ERK-1 and -2, STAT3, p38 MAPK and Akt were
utilized (PD98059, WP1066, SB235090 and LY204002 respec-
tively). None of these inhibitors significantly blocked the
cardioprotective effect of FL3 on H9c2 cardiomyocytes treated
with doxorubicin (data not shown). Since phosphorylation of a
small heat shock protein Hsp27 induces a cascade of events that
protect cardiomyocytes from many stresses [22–25], we examined
whether this protein is involved in FL3-survival signaling pathway.
Interestingly, KRIBB3, an inhibitor of Hsp27 [26], completely
reversed FL3-mediated cardioprotective effect (Fig. 4A). Since
inhibition of the Hsp27 compromised the cardioprotective effects
of FL3, the ability of FL3 to activate this pathway was evaluated
and quantified by Western blot analysis and densitometry, using
antibodies specific for Hsp27 phosphorylated on Serine 15.
Figure 4B illustrates original Western blot analyses that FL3
induces Hsp27 phosphorylation, reaching to maximum level
within 1 h without altering the level of total Hsp27 protein as
quantified and shown in Figure 4C (n=3, P,0.05). Involvement
of Hsp27 in the cytoprotective effect of FL3 was further confirmed
by knocking-down Hsp27. As shown in Figure 4D, FL3-mediated
protection of H9c2 cells against apoptosis induced by doxorubicin
was completely reversed in H9c2 cells where Hsp27 expression
was knocked-down as compared to FL3 effect on control H9c2
cells.
FL3 protects against doxorubicin-induced cardiotoxicity
in vivo
To further explore the cardioprotective effect of FL3 in vivo,5
groups of mice received different treatments, according to the
protocol shown in Figure 5A. At day 12, doxorubicin-treated
animals had a compromised survival rate (31%; n=45), and there
was a remarkable increase in survival rate in mice treated with
FL3+doxorubicin (56%; n=36) (P=0.024, corrected Fisher’s
exact P=0.04)’’ (Figure 5B). The toxicity of doxorubicin was also
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However, mice pretreated with FL3 exhibited only a 13% (n=45,
p,0.01) loss of body weight. Mice treated with doxorubicin
displayed also a marked reduction in heart weight at day 4 that
was significantly alleviated by the pretreatment with FL3
(Supplementary Figure S2). Note that the survival rates of animals
in the control group and FL3 alone group were consistently 100%
in all series of experiments. This data indicates also that FL3
displays a proper bioavailability.
We next analyzed morphological changes in all surviving mice at
the 12 days. The myocardial pathology associated with doxorubicin
treatment, including myocyte loss and fibrosis. Representative
staining of heart sections by Mallory tetrachrome can be seen in
Figure 5C for doxorubicin and FL3+doxorubicin treated hearts,
demonstrating significantly less fibrotic tissue (blue) in FL3+
doxorubicin treated group. The fibrotic area was reduced in the
FL3+doxorubicin treated group as compared with doxorubicin
treated groups (Figure 5D, histogram, n=4, *P,0.001). No
cardiomyocyte pathology and fibrosis were detected in the vehicle-
treated control or FL3 alone-treated groups. Quantitative RT-PCR
analyses demonstrated that FL3 reversed the increase of expression
of collagen 2a1 induced by doxorubicin, confirming the antifibrotic
activity of FL3 (Supplementary Figure S3). Representative TUNEL
(green) stained heart sections are shown in Figure 5D, demonstrat-
ing fewer apoptotic cells in the FL3-treated mouse heart.
Quantitative analyses by TUNEL assay on the heart sections
revealed a significant decrease in cell death in FL3+doxorubicin
treated hearts as compared to doxorubicin alone treated hearts
(n=3,*P,0.05,Figure5D,histogram).Thisisconsistent withthein
vitro cardioprotective effect of FL3 in H9c2 cells (Figure 2C). RT-
PCR analyses revealed that FL3 treatment prevented doxorubicin-
induced decreased expression of connexin 43 (Supplementary
Figure S3), a cardiomyocyte gap junction channel gene that is
involved in cellular communication and mitochondrial apoptosis
[27,28].AlltogetherthesefindingscanaccountfortheabilityofFL3
to attenuate the deleterious effect of doxorubicin on fibrosis,
apoptosis and intercardiomyocyte communication.
To further examine whether these beneficial effects of FL3
contributetoitsprotectionagainst theadverseeffectsofdoxorubicin
on the contractions of cardiomyocytes, the expressions of intracel-
lular Ca
2+ handling genes as indicators of changes in cardiomyocyte
contractility were assessed. In agreement with the previous studies,
doxorubicin-treated mice hearts exhibited reduced level of Ca
2+
handling genes such as the sarcoplasmic/endoplasmic reticulum
Ca
2+ ATPases (SERCA), phospholamban and the ryanodin
receptor. FL3 treatment prevented doxorubicin-induced decreased
expression of SERCA2a, phospholamban and the ryanodin
receptor (Figure 5E). Consistent with the ability of FL3 to attenuate
the adverse effects of doxorubicin on the development of fibrosis
and cell death, FL3 also prevented the decline in calcium handling
gene expression, thereby improving cardiac contractility.
Discussion
This study is the first attempt to characterize the beneficial effect
of a flavagline in doxorubicin-induced cardiac damage. Cardio-
Figure 1. Flavaglines FL1–4 protect H9c2 cardiomyocytes from apoptosis induced by 1 mM doxorubicin. H9c2 cells were pretreated
with flavaglines FL1–4 or their vehicle for 10 h and then treated with doxorubicin for additional 14 h (acute model of cardiotoxicity). Survival rate was
quantified by FACS analysis. Histogram shows total population of surviving cells after different concentration of flavagline and doxorubicin
treatments. Remarkably, incubation of H9c2 cells with 50 or 100 nM FL3 induced a cardioprotection of 61 and 67% respectively. The structure of the
tested compounds is shown in the right panel. * indicates p,0.01 (n=4).
doi:10.1371/journal.pone.0025302.g001
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use of anthracyclines in cancer chemotherapy. The search for
cardioprotective agents that alleviate anthracyclines cardiotoxicity
in the last 30 years has led only to dexrazoxane [29]. This iron
chelator is the only cardioprotective agents with proven efficacy in
cancer patients receiving anthracycline treatment. However, its
effectiveness is limited, and even not established in children [30].
Although a number of alternative cardioprotective strategies have
been assessed in animal models, none of them have been clinically
validated yet [31,32].
The unique biological profile of flavaglines has attracted
considerable interest these last ten years, [8,33]. Although
neuroprotective effects of flavaglines have been described [9],
our data unravel for the first time the potential of flavaglines in the
prevention of anthracycline cardiotoxicity. As shown in Figure 1,
FL3 displayed a stronger cardioprotection that FL1, which is the
racemate of the natural compound rocaglaol, indicating a
preference for a bromine over a methoxy in the phenyl moiety
in position 5. Deletion of this methoxy or its displacement to the
adjacent phenyl moiety was greatly detrimental for cardioprotec-
tion.
The cardioprotective action of flavaglines was not restricted to
damages induced by doxorubicin in the cultured cardiomyocytes.
FL3 strongly reduced also the apoptosis induced by serum
starvation. Interestingly these stresses are of different nature:
doxorubicin induces an oxidative stress, while serum starvation
Figure 2. Protection of H9c2 cardiomyocytes by FL3 against doxorubicin-induced apoptosis. A. Histogram shows % of apoptotic cells in
vehicle, FL3 (100 nM), doxorubicin (1 mM) and FL3+doxorubicin treated H9c2 cells detected by FACS analyses (n=4, P,0.01). B. Original illustration
of total apoptotic cells detected by FACS analyses among the cell population pretreated with FL3 (0–100 nM) and treated with doxorubicin (1 mM). C.
Representative illustration of TUNEL positive apoptotic cells (green) versus Dapi (blue) positive total cells detected by fluorescent microscopic
analyses for doxorubicin (DOX) and FL3+ DOX treated cells (n=3, P,0.001). D. Histogram shows quantification of % of apoptosis (TUNEL positive
cells versus Dapi positive total number of cells) for different concentration of FL3 (10–100 nM) in a chronic model of cardiotoxicity induced by
doxorubicin (1 mM) (n=3, P,0.001). E. Representative illustration of Western blot analyses on vehicle, doxorubicin, FL3 itself and FL3+doxorubicin
treated cells, using active caspase-3 antibody and GAPDH antibody to normalize the assay. Quantitative analysis of Western blots is shown in
histogram as % of caspase-3 activity over the vehicle (n=3, P,0.01).
doi:10.1371/journal.pone.0025302.g002
Figure 3. FL3 protects H9c2 cardiomyocytes against serum
starvation. Histogram shows quantification of percentage of apo-
ptotic cells in H9c2 cells that were cultured in 1% serum in presence of
vehicle or FL3 (20 nM) for different time periods as detected by FACS
analyses (n=3, P,0.01).
doi:10.1371/journal.pone.0025302.g003
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mimicking an important component of myocardial ischemia.
Our study presents the first evidence that flavaglines display
their cytoprotective effect by inducing the phosphorylation of
Hsp27. This small heat shock protein has recently emerged as a
critical factor for the protection of cells against many insults,
through a myriad of functions including chaperone activity,
mRNA stabilization, maintenance of cytoskeletal architecture,
control of redox homeostasis, and inhibition of apoptosis [22].
Consistent with our findings, overexpression of Hsp27 and
hyperthermia-induced phosphorylation of Hsp27 were shown to
strongly protect cardiomyocytes against doxorubicin insult
[25,34]. The identification of the molecular target of flavaglines
and the detailed molecular mechanism of Hsp27 activation
underlying flavagline cardioprotection are currently under inves-
tigation.
Cardioprotective effect of FL3 was demonstrated in an in vivo
model as well. A single dose of doxorubicin induced a severe
myocyte loss due to apoptosis and fibrosis in heart, which lead to a
loss of heart weight and a mortality rate of 69%. This loss of heart
weight is characteristic of this model of acute cardiotoxicity
following a single injection of doxorubicin in adult mice [35–37]
(while models of chronic doxorubicine-induced cardiotoxicity
generally lead to an increase of heart weight due to cardiac
hypertrophy). Agreement with the protective efficacy of FL3 in
H9c2 cardioblasts, treatment of mice with FL3, prevented
doxorubicin-induced apoptosis and fibrosis in heart and reduced
mortality to 44%. Together with the in vitro studies showing that
FL3 signaling produces a direct anti-apoptotic effect in cultured
H9c2 cardioblasts, our in vivo results suggest that prevention of
apoptosis is a possible mechanism of FL3-mediated cardioprotec-
tive effects against the effects of doxorubicin. Even though we did
not directly compare the effect of dexrazoxane in our study, based
on previous reports, it appears that FL3 is as effective as this
clinically used cardioprotective agent in mice model [38]. Our
previous in vivo study showed that FL3 alone does not induce any
loss of weight or any other sign of toxicity in mice [14].
Previous studies showed that doxorubicin decreased calcium
handling gene expression in cultured new born [39], adult rat
ventricular cardiomyocytes [40], and rabbit in vivo model of
doxorubicin cardiotoxicity [41,42], leading to myocardial dys-
function [28]. In concert with the previous studies, here we
illustrated that doxorubicin treated mice hearts exhibited reduced
level of these Ca
2+ handling genes, as indicators of a sarcoplasmic
and contractility dysfunction. FL3 treatment prevented attenua-
tion of these genes, indicating that FL3 significantly alleviated
these signs of cardiac dysfunction induced by doxorubicin.
Taken together, reduced heart weight and contractile gene
expression, increased apoptosis and fibrosis, are the principal signs
of the cardiotoxicity of doxorubicin. Combining our in vitro in the
cardiomyocytes and in vitro in mice, our data clearly demonstrated
that FL3 treatment attenuated these adverse effects of doxorubicin
and significantly increased the survival rate in vivo.
Collectively, our in vitro and in vivo data provide the first evidence
of the cardioprotective effects of FL3 against the adverse effects of
doxorubicin on the structure and function of heart.
Flavaglines exhibit not only cardioprotective, but also neuro-
protective effects. In addition to their anticancer and cardiopro-
Figure 4. FL3 protects H9c2 cardiomyocytes by inducing Hsp27 phosphorylation. A. Quantification of the FACS analysis on H9c2
cardiomyocytes that were treated with doxorubicin (1 mM), FL3 (100 nM) in the presence or absence of Hsp27 inhibitor KRIBB3 (1 mM). B.
Representative Western blot analysis on H9c2 cell lysates treated with vehicle or FL3 (100 nM) for 1 h or 4 h, utilizing antibody that recognize either
phosphorylated (Ser-15 ) form of Hsp27 (upper) and total Hsp27 protein (lower bands). C. Quantitative analysis of the Western blots (%
phosphorylated Hsp27 over total Hsp27 (n=3, p,0.05). D. Histogram shows % of apoptotic cells on H9c2 control or H9c2 cells where Hsp27
expression was reduced by transfection of siRNA for Hsp27. Remarkably, in the H9c2 cells-knockdown for Hsp27, the cardioprotective effect of FL3
(100 nM) was completely reversed without modifying basal and doxorubicin-induced apoptosis as compare to H9c2 control cells (n=3, p,0.05).
doi:10.1371/journal.pone.0025302.g004
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administration of compounds in mice model of doxorubicin-induced cardiotoxicity. B. Kaplan-Meier survival curves for mice (n=45) treated with
either doxorubicin (15 mg/kg i.p.) or doxorubicin +5 injections of FL3 (12.5 mg/kg i.p.). The survival rate significantly increased in the FL3+doxorubicin
group (n=45) compared with doxorubicin-treated animals (56 versus 31%, p=0.024). There was no mortality in the control group and FL3 group. C.
In vivo myocardium fibrosis. Representative illustration of Malory tetrachrome staining for doxorubicin (DOX) and FL3+DOX treated mice hearts,
demonstrating different degrees of fibrosis (blue) in their hearts. The histogram shows the quantification of fibrotic areas (density/pixels
2) in the
cryosectioned hearts of 4 groups of mice. D. In vivo myocardial apoptosis. Representative TUNEL positive (green) apoptotic area in heart tissue
sections from animals treated with DOX and FL3+DOX, original magnification is 620. Dapi is a nucleus marker (blue). The FL3+doxorubicin groups
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tective effects of flavaglines in animal models of stroke and
Parkinson disease [9]. Interestingly, recently Pelletier and
collaborators showed that flavaglines enhance doxorubicin
chemosensitivity in a mouse lymphoma model [43]. Albeit this
profile of pharmacological activities of flavaglines is original, it is
not unique: tetracyclines, which are broad-spectrum antibiotics,
are currently undergoing clinical trials not only for several types of
cancers, but also for neurological and cardiovascular diseases
(Huntington, Parkinson and Alzheimer’s diseases, coronary artery
bypass and post-myocardial infarction remodeling) [44]. A
tetracycline was shown to alleviate also doxorubicin-induced
cardiotoxicity in mice [45]. Similarly, histone deacetylase
inhibitors, which were originally developed to treat cancers, have
emerged as promising drug candidates for the treatment of heart
failure and neurodegenerative disorders [46]. The benefit of an
association of flavaglines to anthracyclines might be double: these
compounds could enhance the anticancer effects of anthracyclines
[14] and alleviate their main adverse effect, cardiotoxicity.
Considering that anthracyclines are the most widely used
anticancer drug, the discovery of a new class of cardioprotective
agents is of paramount importance in clinic, and further studies to
validate these hypotheses are warranted. The results of this study
raise also the possibility that flavaglines may protect other organs
than heart against the damaging effects of cancer chemotherapies,
suggesting that these compounds deserve further extensive
preclinical investigations.
Supporting Information
Figure S1 Protection of H9c2 cardiomyocytes grown in
a complete medium (10% serum) by FL3 against
doxorubicin-induced apoptosis. Histogram shows % of
apoptotic cells in vehicle, FL3 (100 nM), doxorubicin (1 mM)
and FL3+doxorubicin treated H9c2 cells detected by FACS
analyses (n=5, p,0.05).
(TIF)
Figure S2 The heart weight as an indirect sign of
cardiomyopathy in mice treated with doxorubicin and/
or FL3. Histogram shows the heart weight (mg) of mice treated
with vehicle, FL3 (5 injections at 12.5 mg/kg i.p.), doxorubicin
(15 mg/kg i.p.) or doxorubicin+FL3 according to the general
protocol displayed in Figure 5A. Mice were euthanized 4 days
after the administration of doxorubicin or vehicle and hearts were
weighted.
(TIF)
Figure S3 In vivo cardioprotective activity of FL3
against doxorubicin-induced modification of fibrotic
and cardiomyocyte structural gene expression. Quantita-
tive RT PCR analyses for collagen 1a1, collagen 2a1 and
connexion 43 were performed on RNA extracted from hearts of
mice treated with vehicle, doxorubicin or doxorubicin+FL3
according to the general protocol displayed in Figure 5A. Mice
were euthanized 4 days after the administration of doxorubicin or
vehicle and hearts were taken off for RNA extraction. * indicates
p,0.05 as compare to vehicle, { indicates p,0.05 as compare to
doxorubicin group.
(TIF)
Table S1 Primers used to analyze gene expression by
RT-PCR.
(DOC)
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